Clinical trials: Dermatologic Diseases
Atopic Dermatitis, Eczema
Cardamom and Topical Roseomonas in Atopic Dermatitis
Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep…
- Trial name
- NCT06096857
- Testing
- Roseomonas mucosa (RSM2015) and Cardamom seeds
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HER2-positive Locally Advanced or Metastatic Breast Cancer
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of pertuzumab, trastuzumab and chemotherapy as a pertuzumab retreatment compared to trastuzumab and chemotherapy in locally advanced or metastatic breast cancer…
- Trial name
- PRECIOUS (NCT02514681)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 3 sites in Japan
- Volunteers
- 226 people
- Sponsor
- Japan Breast Cancer Research Group
Dermatitis, Atopic
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- GENESIS (NCT04791319)
- Testing
- Bermekimab, Dupilumab
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 199 people
- Sponsor
- Janssen Research & Development, LLC
Cytotoxic Drugs, Romiplostim N01
Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients
The primary study objective: To evaluate the efficacy of romiplostim (N01) in the treatment of chemotherapy-induced thrombocytopenia (CIT) in breast cancer patients by assessing the proportion of patients whose platelet count…
- Conditions
- Cytotoxic Drugs, Romiplostim N01, Breast Cancer
- Trial name
- NCT07162519
- Testing
- romiplostim N01
- Volunteers
- 68 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Rapid Histologic Assessment for Stereotactic Breast Biopsy: Enhancing Early Detection With Miniature Mass Spectrometry and AI
Breast cancer is the leading cancer among Taiwanese women, and it is the second leading cause of cancer-related deaths in women.
- Trial name
- NCT06663228
- Testing
- MMS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Metastatic Melanoma
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients
This was a retrospective, non-interventional, registry study based on secondary electronic medical record (EMR) data collected in Helsinki and Uusimaa hospital district (HUS data lake), hospital district of Southwest Finland…
- Trial name
- NCT06369428
- Where
- Switzerland
- Volunteers
- 1,795 people
- Sponsor
- Novartis
Breast Cancer
Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy
Breast cancer has become the world's number one cancer. While its therapeutic efficacy is increasing, how to achieve non-invasive evaluation of the efficacy of neoadjuvant therapy (NAT) for breast cancer patients and thus avoid…
- Trial name
- NCT06649565
- Testing
- no intervention
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Postoperative Analgesia, Hand Strength
Long-term Outcomes of Breast Cancer Patients After Wound Infiltration Analgesia
In the study that was conducted from 05.01.2009 - 31.12.2012. 120 patients were examined. By drawing random numbers, the patients were randomized into 3 groups for postoperative analgesia: 1. Diclofenac 2 mg/kg/day - control, 2.
- Conditions
- Postoperative Analgesia, Hand Strength, Health Related Quality of Life, Chronic Shoulder Pain
- Trial name
- NCT05829707
- Testing
- Diclofenac Sodium, Levobupivacaine bolus analgesia, Levobupivacaine PCA group
- Volunteers
- 120 people
- Sponsor
- Osijek University Hospital
Chronic Spontaneous Urticaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.
This is a randomized, double-blind, placebo-controlled phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HS-10561 capsule in healthy Chinese adults and patients with…
- Trial name
- NCT06864507
- Testing
- HS-10561
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Psoriasis
A Study of Ixekizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam)…
- Trial name
- NCT02993471
- Testing
- Drug Cocktail, Ixekizumab
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Atopic Dermatitis
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic…
- Trial name
- NCT01137032
- Testing
- Pandel Cream 0.1%
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Breast Cancer, Colon Cancer
The PAI Trial for Breast and Colon Cancer Survivors
The purpose of the study is to determine if a Physical Activity Index (PAI) tool that collects measures on physical activity, strength training and sedentary behavior can be used in a clinical setting to monitor patient behavior…
- Trial name
- NCT05156463
- Testing
- PAI Tool and Exercise Coaching
- Volunteers
- healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Solid Tumor, Melanoma
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Melanoma, HNSCC, Sarcoma
- Trial name
- NCT04370587
- Testing
- T3011, T3011 + pembrolizumab
- Where
- 9 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- ImmVira Pharma Co. Ltd
Stage I Breast Cancer
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with…
- Trial name
- DEBRA (NCT04852887)
- Testing
- Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- Where
- 832 sites in United States, Canada and 2 more
- Volunteers
- 1,670 people
- Sponsor
- NRG Oncology
Breast Cancer
Effects of Risk Presentation Format and Frequently Asked Questions on Breast Cancer Risk Skepticism
The purpose of this study is to find out whether the way a breast cancer risk estimate is presented affects how women feel about their risk and whether they believe the estimate is accurate for them.
- Trial name
- NCT07793721
- Testing
- Risk Presentation Format, Frequently Asked Questions Exposure
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Ehlers-Danlos Syndrome
Vision-based Assessment of Joint Extensibility in Ehlers Danlos Syndrome
Ehlers Danlos Syndrome (EDS) is a heterogenous group of genetic disorders with 13 identified subtypes. Hypermobile EDS (hEDS), although the most common subtype of EDS, does not yet have an identified genetic mutation for…
- Trial name
- NCT05366114
- Testing
- No intervention, additional video data collection only
- Where
- Canada
- Volunteers
- 225 people
- Sponsor
- University Health Network, Toronto
Breast Cancer, Cardiotoxicity
The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
The purpose of this study is to determine if exercise preconditioning can mitigate the off target effects of chemotherapy treatment on measures of cardiovascular function, inflammatory responses, and quality of life.
- Conditions
- Breast Cancer, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- NCT05786014
- Testing
- High Intensity Interval Exercise, Moderate Intensity Walking
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Virginia
Breast Neoplasms, Neoplasm Recurrence, Local
Screening MRI for Cancer Recurrence in Patients Treated With Breast Conserving Therapy
A prospective, multicenter study: Primary objective: to assess the diagnostic yield of screening MRI compared to physical examination, mammography or ultrasonography in the detection of recurrence in patients treated with breast…
- Trial name
- NCT01257152
- Where
- South Korea
- Volunteers
- 754 people
- Sponsor
- Seoul National University Hospital
Melasma
Efficiency And Safety Of Association Arbutin, Triamcinolone And Tretinoin In Treatment Of Melasma
The objective of this study is evaluating the clinical activity of the association (tretinoin + arbutin + triamcinolone) in the treatment of epidermal melasma.
- Trial name
- melasma (NCT00717652)
- Testing
- arbutin, tretinoin, triamcinolone, Triluma
- Where
- Brazil
- Volunteers
- 110 people
- Sponsor
- Azidus Brasil
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.
- Conditions
- Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06066138
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.